Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen

Vaccine

Volumn 28, Issue 38, 2010, Pages 6282-6291

  Slütter, Bram ^a   Bal, Suzanne ^a   Keijzer, Chantal ^b   Mallants, Roel ^c   Hagenaars, Niels ^d   Que, Ivo ^e   Kaijzel, Eric ^e   van Eden, Willem ^b   Augustijns, Patrick ^c   Löwik, Clemens ^e   Bouwstra, Joke ^a   Broere, Femke ^b   Jiskoot, Wim ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^d UTRECHT UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Nanoparticles; Nasal delivery; Trimethyl chitosan (TMC)

Indexed keywords

CHITOSAN DERIVATIVE; IMMUNOGLOBULIN G; N TRIMETHYLCHITOSAN; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG FORMULATION; DRUG RELEASE; EMULSION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; VACCINATION; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; CELLS, CULTURED; CHITOSAN; DENDRITIC CELLS; DRUG CARRIERS; FEMALE; HUMANS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOPARTICLES; OVALBUMIN; POLYGLYCOLIC ACID; VACCINATION;

EID: 77955653919     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.121     Document Type: Article

References (46)

1. Debin A., Kravtzoff R., Santiago J.V., Cazales L., Sperandio S., Melber K., et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 2002, 20:2752-2763.
2. 8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(d,l-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 2007, 81:652-662.
3. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Vyas S.P. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm 2008, 354:235-241.
4. Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005, 23:4367-4374.
5. Revaz V., Zurbriggen R., Moser C., Schiller J.T., Ponci F., Bobst M., et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 2007, 76:75-85.
6. Sloat B.R., Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 2006, 23:262-269.
7. Sorichter S., Baumann U., Baumgart A., Walterspacher S., von Specht B.U. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine 2009, 27:2755-2759.
8. Koping-Hoggard M., Sanchez A., Alonso M.J. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 2005, 4:185-196.
9. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006, 24:4201-4211.
10. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21:67-77.
11. Vila A., Sanchez A., Evora C., Soriano I., McCallion O., Alonso M.J. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 2005, 292:43-52.
12. Sharma S., Mukkur T.K., Benson H.A., Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 2009, 98:812-843.
13. Slütter B., Hagenaars N., Jiskoot W. Rational design of nasal vaccines. J Drug Target 2008, 16:1-17.
14. Corrigan O.I., Li X. Quantifying drug release from PLGA nanoparticulates. Eur J Pharm Sci 2009, 37:477-485.
15. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., Pedraz J.L. Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. Vaccine 2002, 20:2181-2190.
16. Lemoine D., Deschuyteneer M., Hogge F., Preat V. Intranasal immunization against influenza virus using polymeric particles. J Biomater Sci Polym Ed 1999, 10:805-825.
17. Boddohi S., Moore N., Johnson P.A., Kipper M.J. Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan. Biomacromolecules 2009, 77:60-68.
18. Gan Q., Wang T., Cochrane C., McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 2005, 44:65-73.
19. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010, 62:59-82.
20. Amidi M., Romeijn S.G., Verhoef J.C., Junginger H.E., Bungener L., Huckriede A., et al. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 2007, 25:144-153.
21. Sayin B., Somavarapu S., Li X.W., Thanou M., Sesardic D., Alpar H.O., et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm 2008, 363:139-148.
22. Pawar D., Goyal A.K., Mangal S., Mishra N., Vaidya B., Tiwari S., et al. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010, 12:130-137.
23. Bal S.M., Slütter B., van Riet E., Kruithof A.C., Ding Z., Kersten G.F., et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J Control Release 2009, 142:374-383.
24. Ghassemi A.H., van Steenbergen M.J., Talsma H., van Nostrum C.F., Jiskoot W., Crommelin D.J., et al. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid). J Control Release 2009, 138:57-63.
25. Slütter B., Soema P.C., Ding Z., Verheul R., Hennink W., Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release 2010, 143:207-214.
26. Jorissen M., Van der Schueren B., Tyberghein J., Van der Berghe H., Cassiman J.J. Ciliogenesis and coordinated ciliary beating in human nasal epithelial cells cultured in vitro. Acta Otorhinolaryngol Belg 1989, 43:67-73.
27. Mallants R., Jorissen M., Augustijns P. Effect of preservatives on ciliary beat frequency in human nasal epithelial cell culture: single versus multiple exposure. Int J Pharm 2007, 338:64-69.
28. Dimova S., Maes F., Brewster M.E., Jorissen M., Noppe M., Augustijns P. High-speed digital imaging method for ciliary beat frequency measurement. J Pharm Pharmacol 2005, 57:521-526.
29. Hagenaars N., Mania M., de Jong P., Que I., Nieuwland R., Slütter B., et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 2010, 144:17-24.
30. van de Weert M. Structural integrity of pharmaceutical proteins in polymeric matrices 2001, Utrecht University, Utrecht.
31. Fujimura Y., Akisada T., Harada T., Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol 2006, 39:181-186.
32. Jung T., Kamm W., Breitenbach A., Hungerer K.D., Hundt E., Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 2001, 18:352-360.
33. Sandri G., Bonferroni M.C., Rossi S., Ferrari F., Gibin S., Zambito Y., et al. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm 2007, 65:68-77.
34. Baca-Estrada M.E., Foldvari M., Snider M. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res 1999, 19:455-462.
35. Joseph A., Itskovitz-Cooper N., Samira S., Flasterstein O., Eliyahu H., Simberg D., et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 2006, 24:3990-4006.
36. Hagenaars N., Mastrobattista E., Verheul R.J., Mooren I., Glansbeek H.L., Heldens J.G., et al. Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharm Res 2009, 26:1353-1364.
37. Slütter B., Plapied L., Fievez V., Alonso Sande M., des Rieux A., Schneider Y.J., et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 2009, 138:113-121.
38. Amidi M., Romeijn S.G., Borchard G., Junginger H.E., Hennink W.E., Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release 2006, 111:107-116.
39. Verheul R.J., Amidi M., van der Wal S., van Riet E., Jiskoot W., Hennink W.E. Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. Biomaterials 2008, 29:3642-3649.
40. Luzardo-Alvarez A., Blarer N., Peter K., Romero J.F., Reymond C., Corradin G., et al. Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J Control Release 2005, 109:62-76.
41. Kanchan V., Katare Y.K., Panda A.K. Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. Biomaterials 2009, 30:4763-4776.
42. Waeckerle-Men Y., Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005, 57:475-482.
43. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
44. Dal Monte P., Szoka F.C. Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors. J Immunol 1989, 142:1437-1443.
45. Fischer S., Uetz-von Allmen E., Waeckerle-Men Y., Groettrup M., Merkle H.P., Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007, 28:994-1004.
46. Hagenaars N., Verheul R.J., Mooren I., de Jong P.H., Mastrobattista E., Glansbeek H.L., et al. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release 2009, 140:126-133.